Introduction to US Continuous [Glucose Monitoring](/) (CGM) Market
The US CGM market is characterized by an oligopolistic structure, with a limited number of firms dominating the market. According to a market research report [1], Dexcom and Abbott are the leading manufacturers, while Medtronic and Senseonics hold specialized market shares.
Market Structure and Competition
The market leaders, Dexcom and Abbott, have distinct product lines and strategies. Dexcom focuses on interoperability, with its G6 and G7 product lines being compatible with Automated Insulin Delivery (AID) systems like Tandem and Omnipod [2]. In contrast, Abbott dominates the Type 2 and cost-sensitive markets with its FreeStyle Libre 2 and 3, leveraging high-volume manufacturing and 'wired enzyme' technology [3].
Specialized Players and Niche Markets
Medtronic operates a closed ecosystem, where its sensors (Guardian 4, Simplera) function exclusively with its own insulin pumps, focusing on system integration rather than standalone sensor performance [4]. Senseonics, on the other hand, offers the only implantable solution, the Eversense E3, utilizing fluorescence technology for 6-month wear, targeting users with adhesive allergies or sensor fatigue [5].
Industry Trends and Future Developments
The CGM industry is evolving, with a trend toward the development of smaller, fully disposable, all-in-one devices with shorter warm-up times and factory calibration [6]. This shift is expected to enhance user convenience and overall CGM experience.
Conclusion
In conclusion, the US CGM market is characterized by a mix of market leaders and specialized players, each with distinct product lines and strategies. The industry is moving toward more convenient and user-friendly devices, with a focus on interoperability, miniaturization, and factory calibration.